

Stress-hyperglycemia, insulin and immunomodulation in sepsis

Abstract Stress-hyperglycemia and insulin resistance are exceedingly common in critically ill patients, particularly those with sepsis. Multiple pathogenetic mechanisms are responsible for this metabolic syndrome; however, increased release of pro-inflammatory mediators and counter-regulatory hormones may play a pivotal role. Recent data suggests that hyperglycemia may potentiate the pro-inflammatory response while insulin has the opposite effect. Furthermore, emerging evidence

suggests that tight glycemic control will improve the outcome of critically ill patients. This paper reviews the pathophysiology of stress hyperglycemia in the critically ill septic patient and outlines a treatment strategy for the management of this disorder.

Keywords Insulin · Glucose · Sepsis · Sepsis syndrome · Critical illness · Insulin resistance · Hyperglycemia

Introduction

In recent decades the reported incidence of sepsis has increased dramatically, largely due to the advancing age of the population, an increased number of invasive procedures being performed and immunosuppressive therapy [1]. In the United States, approximately 750,000 cases of sepsis occur each year, at least 225,000 of which are fatal [2]. Despite the use of antimicrobial agents and advanced life-support care, the case fatality rate for patients with sepsis has remained between 30 and 40% over the past three decades [2, 3].

When the body is challenged by foreign microbial agents homeostatic mechanisms come into play that attempt to rid the body of the foreign agent without damaging the host. This involves the activation of pro- and anti-inflammatory pathways which are tightly controlled and regulated [4]. In most infected persons, the body is able to achieve a balance between pro-inflammatory and anti-inflammatory mediators and homeostasis is restored. In some patients, however, this balance is upset with an excessive pro-inflammatory response re-

sulting in the systemic inflammatory response syndrome (SIRS), multisystem organ dysfunction, and ultimately death [4, 5, 6, 7]. Attempts at down-regulating the pro-inflammatory response with novel agents directed at specific pro-inflammatory mediators has uniformly met with failure [4, 8, 9, 10]. Recent provocative data suggests that tight glycemic control with insulin may restore the balance between pro-inflammatory and anti-inflammatory mediators and improve the outcome of critically ill patients [11, 12].

In this article we review the physiology of stress hyperglycemia and the immune-modulatory role of insulin in critically ill patients. The reader should be cautioned that many of the studies quoted in our review were performed in non-critically ill patients, many of whom were diabetic. While it is likely that the pathogenetic pathways are similar in both groups of patients, many of these postulates remain unproven in the critical care setting.

Endocrinology of stress

Stress associated with critical illness is characterized by activation of the hypothalamic–pituitary–adrenal (HPA) axis with the release of cortisol from the adrenal gland [13]. Activation of the HPA axis with the release of cortisol is an essential component of the general adaptation to illness and stress and contributes to the maintenance of cellular and organ homeostasis.

In addition to increased cortisol secretion the stress response is characterized by a marked increase in the release of norepinephrine and epinephrine as well as glucagon and growth hormone [14, 15, 16]. Insulin levels are usually normal or decreased, despite peripheral insulin resistance [17, 18, 19]. It has been suggested that insulin release may be suppressed as the result of increased activation of the pancreatic alpha receptors [19]. In addition to causing insulin resistance, interleukin-1 (IL-1) and tumor necrosis factor- α (TNF- α) inhibit insulin release, an effect which appears to be concentration dependent [20]. The low to normal insulin levels together with insulin resistance in the presence of increased secretion of the counter-regulatory hormones results in stress hyperglycemia (see discussion below).

Glucose transporters and the mechanism of insulin action

Glucose is normally taken up across the cellular membranes by a system of carrier-mediated facilitated transport [21]. Five transporter isoforms exist. Three of the isoforms, GLUT 1, GLUT 2, and GLUT 4, are important for glucose uptake [21]. GLUT 1 can be found in many tissues and is responsible for basal uptake. It has a high affinity for glucose and it ensures transport even under the conditions of hypoglycemia. GLUT 2 mediates uptake and release of glucose by hepatocytes and regulation of glucose-stimulated insulin secretion in pancreas. The GLUT2 transporter ensures that the liver is freely permeable to glucose and that glucose transport is not rate-limiting for hepatic glucose uptake. GLUT 4 isoform is involved in glucose transport in tissues where uptake is mediated by insulin which includes skeletal muscle, cardiac muscle, and adipose tissue. Binding of insulin to cell-surface receptors results in autophosphorylation and activation of an intrinsic tyrosine kinase molecule of the insulin receptor (IR) β -subunit. Activated tyrosine kinase subsequently phosphorylates messenger molecular proteins known as insulin receptor substrates (IRS1 and IRS2). The IRS-1 associates with several proteins including the enzyme phosphatidylinositol (PI) 3-kinase. Physiologically insulin increases glucose uptake into the cell by causing translocation of GLUT 4 from intracellular compartments to the plasma membrane. The signaling enzyme molecule PI-3-kinase is essential for insulin

stimulated GLUT 4 translocation [22]. PI-3-kinase also mediates many of the metabolic effects of insulin, including activation of glycogen synthase, protein synthesis, lipogenesis, and the regulation of various genes in insulin-responsive cells including inhibition of phosphoenol pyruvate carboxykinase (PEPCK), the key enzyme of gluconeogenesis.


Mechanisms of stress-induced hyperglycemia and insulin resistance in sepsis

The prevalence of stress hyperglycemia in sepsis and critical illness is difficult to establish due to limited data and variations in the definition of hyperglycemia. Stress hyperglycemia has been previously defined as a plasma glucose above 200 mg/dl [23]; however, in view of the results of the Leuven Intensive Insulin Therapy Trial (see below), stress hyperglycemia should be considered in any critically ill patient with a blood glucose in excess of 110 mg/dl [11]. In a study of septic non-diabetic ICU patients 75% had a baseline blood glucose level above 110 mg/dl [24]. In the Leuven Intensive Insulin Therapy Trial, 12% of patients had a baseline blood glucose above 200 mg/dl; however, 74.5% of patients had a baseline blood glucose above 110 mg/dl, with 97.5% having a recorded blood glucose level above 110 mg/dl sometime during their ICU stay [11].

Changes in whole-body glucose uptake and glucose oxidation in sepsis are complex and may depend on the severity of illness and the stage of the disease. Whole-body glucose uptake and glucose oxidation may be increased in the early stages of sepsis and endotoxemia [25, 26]. This may be the result of cytokine-induced increase in non-insulin mediated glucose uptake by tissues rich in mononuclear phagocytes, including the liver, spleen, ileum, and lung [27, 28]. Enhanced non-insulin mediated glucose uptake appears to result from an increase in the synthesis, concentration or activity of the GLUT1 transporter [29, 30]. With the development of insulin resistance (see below) glucose utilization and oxidation may decrease [25, 31, 32]. Exogenous insulin increases glucose utilization and oxidation; however, non-oxidative disposal (storage) remains impaired [25, 31, 32].

The metabolic milieu in which stress-induced hyperglycemia develops in the critically ill in the absence of pre-existing diabetes mellitus is complex. A combination of several factors, including the presence of excessive counter regulatory hormones such as glucagon, growth hormone, catecholamines, glucocorticoids, and cytokines such as IL-1, IL-6, and TNF- α combined with exogenous administration of catecholamines, dextrose, and nutritional support together with relative insulin deficiency, play an important role [23]. Increased gluconeogenesis combined with hepatic insulin resistance are the major factors

Fig. 1 Postulated interaction between the insulin signaling pathway and activation of the pro-inflammatory cascade in the pathogenesis of stress hyperglycemia of sepsis. *LPS* lipopolysaccharide, *LBP* lipopolysaccharide binding protein, *TLR4* Toll-like receptor 4, *IκB* inhibitor κ B kinase, *IKK* inhibitor κ B kinase, *IRS-1*, insulin receptor substrate-1, *IL-1* interleukin-1, *TNF* tumor necrosis factor, *NF- κ B* nuclear factor-kappa B



leading to hyperglycemia [33]. Recent human data suggests that hepatic insulin resistance (and PEPCK suppression) remains refractory to intensive insulin therapy [34]. Increased hepatic output of glucose may therefore be more important than peripheral insulin resistance in the genesis of stress hyperglycemia [35]. Gluconeogenic substrates released during stress include lactate, alanine, and glycerol with exogenous glucose failing to suppress gluconeogenesis [16, 36]. Glucagon is the primary hormonal mediator of gluconeogenesis, with septic patients having a significant increase in serum glucagon levels [16]. This effect is mediated by adrenergic stimulation by catecholamines and by cytokines [37]. In addition, cytokines such as $TNF-\alpha$ and $IL-1$ and catecholamines independently and synergistically promote hepatic glucose production [38, 39].

Sepsis is characterized by marked insulin resistance [19, 25, 31, 32, 40, 41]. The insulin resistance in sepsis is directly proportional to the severity of stress response [19]. During sepsis, insulin induced tyrosine phosphorylation of $IRS-1$ and subsequent activation of PI-3-kinase is impaired resulting in defective GLUT-4 receptor translocation, diminished glucose uptake, insulin resistance in skeletal muscle, and hepatic insulin resistance [22]. The mechanism whereby sepsis induces these alterations are unknown, but increased levels of $TNF-\alpha$ may play a key role. Aljada and colleagues have demonstrated that in endothelial cells $TNF-\alpha$ causes a reduction of tyrosine phosphorylation and expression of the insulin receptor [42]. $TNF-\alpha$ diminishes insulin-

induced $IRS-1$ tyrosine phosphorylation in hepatocytes and adipocytes and impairs the activation of PI-3 kinase [43, 44, 45, 46]. These alterations of the early steps in insulin action are probably mediated by $TNF-\alpha$ induced $IRS-1$ serine phosphorylation [43, 46, 47, 48]. Upon serine phosphorylation, $IRS-1$ proteins have a reduced ability to interact with the insulin receptor, to be tyrosine phosphorylated by the insulin receptor and to bind phosphatidylinositol-3 kinase [44, 45].

Recently, Gao and colleagues have demonstrated that activation of the inhibitor κ B kinase (IKK) complex is associated with serine phosphorylation of $IRS-1$ [49]. The IKK is activated by endotoxin via Toll-like receptor 4 ($TLR4$) as well as by $TNF-\alpha$ and interleukin-1 ($IL-1$) [50, 51, 52]. The IKK is a serine kinase that controls the activation of nuclear factor-kappa B ($NF-\kappa B$) a ubiquitous nuclear transcription factor closely associated with the activation of the genes for almost all of the pro-inflammatory mediators [53]. Before activation, $NF-\kappa B$ is bound to inhibitor κ B ($I\kappa B$). This association between $I\kappa B$ and $NF-\kappa B$ results in the cytosolic localization of $NF-\kappa B$. The serine phosphorylation of $I\kappa B$ by the IKK complex results in the degradation of $I\kappa B$ followed by the nuclear translocation of $NF-\kappa B$. The serine phosphorylation of $IRS-1$ and $I\kappa B$ by IKK may partly explain the insulin resistance noted with activation of the pro-inflammatory cascade (see Fig. 1).

Catecholamines have also been shown to inhibit insulin binding, tyrosine kinase activity, and translocation of GLUT-4 either directly through a receptor or a post-

receptor mechanism [54, 55]. Blockade of α_2 adrenergic receptors has been demonstrated to reduce insulin resistance in septic rats [40]. Glucocorticoids impair insulin mediated glucose uptake in skeletal muscle, by down regulating various signaling proteins with resulting inhibition of translocation of GLUT-4 glucose transporter from its internal membrane stores to the plasma membrane [56]. Growth hormone inhibits the insulin pathway by reducing insulin receptors and impairing its activation through phosphorylation on tyrosine residues [57, 58].

Deleterious effects of hyperglycemia in the critically ill

To some extent the deleterious effects of hyperglycemia in the critically ill are similar to that of actual diabetes, although the time scale obviously differs [59]. Stress hyperglycemia but not pre-existing diabetes has been shown to be associated with a worse outcome following acute myocardial infarction and stroke [60, 61, 62, 63, 64, 65, 66]. The plasma glucose level on admission has been shown to be an independent predictor of prognosis after myocardial infarction [60, 61]. In diabetic patients with acute myocardial infarction, therapy to maintain blood glucose at a level below 215 mg/dl improves outcome [62, 63, 64]. The presence of hyperglycemia following an ischemic or hemorrhagic stroke is associated with a two- to threefold increased mortality and significant impairment in functional recovery [65, 66].

Pro-inflammatory effects

Glucose has been shown to be a powerful pro-inflammatory mediator [67], and tight glucose control below 110 mg/dl with insulin has been shown to exert anti-inflammatory effects in the critically ill patient [68]. The oral administration of 75 g of glucose to healthy volunteers increases reactive oxygen species (ROS) generation by polymorphonuclear leukocytes and mononuclear cells [69]. Similarly, an oral glucose load has been demonstrated to increase plasma IL-8 levels [70]. Chettab and coworkers have demonstrated that hyperglycemia up-regulates the IL-8 gene [71]. IL-8 is a potent neutrophil chemoattractant, playing an important role in inflammation [72, 73, 74]. Glucose induces an increase in intranuclear NF- κ B, a fall in cytosolic I κ B, and an increase in I κ B kinase in vivo and in vitro which are pro-inflammatory [75, 76, 77]. Glucose also has been shown to exert pro-thrombotic effects and to increase oxidative stress due to increased lipid peroxidation [78, 79]. Glucose increases the expression and plasma concentration of matrix metalloproteinase-2 (MMP-2) and MMP-9, which aid in spread of inflammation [80]. Acute hyperglycemia re-

duces endothelial nitric oxide levels, causing abnormal vascular reactivity and organ perfusion [81].

Increased susceptibility to infection

In diabetic patients hyperglycemia has long been known to increase the susceptibility to infections [82]. In critically ill surgical and burn patients tight glycemic control has been demonstrated to reduce the risk of septic morbidity [11, 83, 84, 85]. The in vitro responsiveness of leukocytes stimulated by inflammatory mediators is inversely correlated with glycemic control [86, 87]. Rassias and colleagues demonstrated that tight glycemic control partially prevented the postoperative decrease in neutrophil phagocytic activity [88]. In addition, hyperglycemia has been demonstrated to decrease the oxidative burst of leukocytes [89, 90].

Immune-modulatory role of insulin in sepsis

Besides control of hyperglycemia, insulin has potent acute anti-inflammatory effects. In a group of obese subjects, Dandona and colleagues demonstrated that an infusion of insulin was associated with a significant fall of intranuclear NF- κ B, and increase in I κ B in mononuclear cells [91]. These changes were associated with a fall in the generation of reactive oxygen species and a fall in the serum levels of soluble intercellular adhesion molecule-1 (sICAM-1), monocyte chemoattractant protein-1 (MCP-1), and plasminogen activator inhibitor-1 (PAI-1) [91]. In a similar experiment Aljada et al. demonstrated that insulin decreased expression of the pro-inflammatory transcription factor, early growth response-1 (EGR-1), and this was associated with a significant fall in plasma tissue factor (TF) and PAI-1 levels [92]; thus, while hyperglycemia has pro-thrombotic effects, insulin has anti-thrombotic and fibrinolytic effects by suppressing TF and PAI-1.

One mechanism underlying the anti-inflammatory effect of insulin may be through the release of nitric oxide (NO) from the endothelium. Insulin has been demonstrated to induce an increase in the expression NO synthase (NOS), the enzyme that generates NO [93]. The NO has been demonstrated to down-regulate the expression of endothelial cell adhesion molecules (ECAMs) as well as the pro-inflammatory cytokines [94, 95, 96, 97, 98]. While the anti-inflammatory effects of NO have not been fully delineated, it is thought that NO inhibits the activation of NF- κ B. Several authors have demonstrated that NO *S*-nitrosylates a key thiol group in the DNA binding domain of NF- κ B p50 and that this is associated with decreased gene transcription and synthesis of NF- κ B [96, 99, 100].

NF- κ B as a therapeutic target for tight glycemic control

NF- κ B is a nuclear transcription factor involved in the regulation of over 150 genes related to inflammation, including TNF- α , IL-1, IL-6, IL-8, cyclooxygenase-2, and inducible nitric oxide synthase [53, 101]. Excessive activation of NF- κ B has been identified as a marker of poor prognosis in sepsis [102, 103, 104]. Emerging data suggests that NF- κ B may be a therapeutic target for the adjuvant treatment of sepsis [105, 106, 107, 108]. The data cited above suggests that tight glycemic control with insulin may decrease NF- κ B activation. This hypothesis is supported by the Leuven Intensive Insulin Therapy Trial in which mannose-binding lectin (MBL) and C-reactive protein (CRP) levels were significantly suppressed by intensive insulin therapy [68].

Intensive insulin therapy in the critically ill

Van Den Berghe et al. in a prospective randomized controlled study involving 1548 patients demonstrated that intensive insulin therapy reduced mortality and morbidity among patients admitted to a surgical critical care unit (the Leuven Intensive Insulin Therapy Trial) [11, 12]. These authors compared an intensive insulin therapy regimen aimed to maintain blood glucose between 80 and 110 mg/dl with conventional treatment in which insulin infusion was only initiated when glucose level was greater than 215 mg/dl and maintenance of glucose between 180 and 200 mg/dl. At 12 months the mortality was 4.6% with the intensive insulin regimen compared with 8.0% in the control group. The benefit was most apparent in patients with greater than 5 days of stay in the intensive care unit. Intensive insulin therapy reduced bloodstream infections by 46%, acute renal failure by 41%, and critical illness poly-neuropathy by 44%. Using multivariate analysis the authors suggested that improved metabolic control, as reflected by normoglycemia, rather than the infused insulin dose per se, was responsible for the beneficial effects of intensive insulin therapy [12]; however, achieving normoglycemia and the administration of insulin are linked, and from the available evidence it appears likely that both factors played a key role in the improved outcome.

The outcome data from the Leuven Intensive Insulin Therapy Trial indicates that there is a dose response curve between the degree of glycemic control and hospital mortality [12]. In the long stay patients (>5 days in the ICU) the cumulative hospital mortality was 15% in patients with a mean blood glucose less than 110 mg/dl, 25% in those with a blood glucose between 110 and 150 mg/dl, and 40% in those with a mean blood glucose of greater than 150 mg/dl. In diabetic patients with acute myocardial infarction, therapy to maintain blood glucose

at a level below 215 mg/dl improves outcome [62, 63, 64]. This data suggests that even “modest” glycemic control will have an impact on patient outcome. This is very important as in the “real world” it may be very difficult (if not somewhat risky) to attempt to maintain a blood glucose in the range of 80–110 mg/dl. This goal may only be achievable in ICUs with a high nursing-to-patient ratio and close physician supervision. On the other hand, the Leuven study showed that in order to improve morbidity by reducing the incidence of bacteremia, acute renal failure, critical illness polyneuropathy, and transfusion requirements, a blood glucose level of <110 mg/dl was required. Indeed, a blood glucose level of 110–150 mg/dl was not effective on these morbidity measures as compared with >150 mg/d [12]. It is also important to note that in the Leuven Intensive Insulin Therapy Trial all patients received between 200 and 300 g of intravenous glucose on the day of admission followed by parenteral or enteral (or both) nutrition started on the second ICU day. In this study tight early glycemic control was associated with the more rapid improvement of insulin resistance [12]. Based on the results of this study we recommend the initiation of parenteral glucose and enteral nutrition in all ICU patients on the day of ICU admission [109, 110, 111] and the initiation of an insulin infusion in patients with a blood glucose above 150 mg/dl (a threshold of 110 mg/dl may be appropriate in select ICUs). Subcutaneous insulin “sliding scales” are not recommended, at least during the first few days, until the patient’s medical condition has stabilized, the blood glucose is well controlled, and the patient has achieved his/her nutritional goal.

Thiazolidinediones are a new class of drugs that are used in the treatment of type-II diabetes mellitus. These drugs reduce insulin resistance through its binding to peroxisome proliferator-activated receptors- λ (PPAR λ). Ghanim and colleagues demonstrated that troglitazone caused a significant fall in cellular NF- κ B with an increase in I κ B in mononuclear cells of diabetic subjects [112]. The changes were associated with a parallel fall in serum levels of TNF- α , sICAM, MCP-1, and PAI-1. While one expects these effects to be useful in chronic situation, it is relevant that these anti-inflammatory were observed within 3–7 days [112, 113]. In an experimental model of acute myocardial infarction, even a single dose of rosiglitazone has been shown to reduce myocardial damage by 50% [114, 115]. Thiazolidinediones may therefore have a role in the metabolic management of patients with sepsis; however, clinical studies are required before these agents can be recommended.

Conclusion

Stress-hyperglycemia and insulin resistance are almost universal findings in patients with sepsis. Multiple pathogenetic mechanisms are responsible for this metabolic

syndrome; however, increased release of pro-inflammatory mediators and counter-regulatory hormones may play a pivotal role. Hyperglycemia per se is pro-inflammatory, whereas insulin has anti-inflammatory properties. Emerging evidence suggests that tight glycemic control with insulin will improve the outcome of critically ill patients.

References

- Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the nited States from 1979 through 2000. *N Engl J Med* 348:1546–1554
- Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. *Crit Care Med* 29:1303–1310
- Friedman G, Silva E, Vincent JL (1998) Has the mortality of septic shock changed with time? *Crit Care Med* 26:2078–2086
- Marik PE, Varon J (2001) Sepsis: state of the art. *Dis Mon* 47:463–532
- Bone RC (1996) Sir Isaac Newton, sepsis, SIRS and CARS. *Crit Care Med* 24:1125–1128
- Bone RC, Sibbald WJ, Sprung CL (1992) The ACCP-SCCM Consensus Conference on sepsis and organ failure. *Chest* 101:1481–1483
- Bone RC, Grodzin CJ, Balk RA (1997) Sepsis: a new hypothesis for pathogenesis of the disease process. *Chest* 112:235–243
- Natanson C, Esposito CJ, Banks SM (1998) The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. *Crit Care Med* 26:1927–1931
- Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C (2002) Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. *Am J Respir Crit Care Med* 166:1197–1205
- Dellinger RP (1999) Severe sepsis trials: Why have they failed? *Minerva Anestesiol* 65:340–345
- van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R (2001) Intensive insulin therapy in critically ill patients. *N Engl J Med* 345:1359–1367
- van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P (2003) Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. *Crit Care Med* 31:359–366
- Marik PE, Zaloga GP (2002) Adrenal insufficiency in the critically ill: a new look at an old problem. *Chest* 122:1784–1796
- Hart BB, Stanford GG, Ziegler MG, Lake CR, Chernow B (1989) Catecholamines: study of interspecies variation. *Crit Care Med* 17:1203–1218
- van den Berghe G (2002) Neuroendocrine pathobiology of chronic illness. *Crit Care Clin* 18:509–528
- Siegel JH, Cerra FB, Coleman B, Giovannini I, Shetye M, Border JR, McMenemy RH (1979) Physiological and metabolic correlations in human sepsis. Invited commentary. *Surgery* 86:163–193
- Clowes GH, Martin H, Walji S, Hirsch E, Gazitua R, Goodfellow R (1978) Blood insulin responses to blood glucose levels in high output sepsis and septic shock. *Am J Surg* 135:577–583
- Dahn MS, Jacobs LA, Smith S, Hans B, Lange MP, Mitchell RA, Kirkpatrick JR (1985) The relationship of insulin production to glucose metabolism in severe sepsis. *Arch Surg* 120:166–172
- Mizock BA (2001) Alterations in fuel metabolism in critical illness hyperglycemia. *Best Pract Res Clin Endocrinol Metab* 15:533–551
- Mehta VK, Hao W, Brooks-Worrell BM, Palmer JP (1994) Low-dose interleukin 1 and tumor necrosis factor individually stimulate insulin release but in combination cause suppression. *Eur J Endocrinol* 130:208–214
- Shepard PR, Kahn BB (1999) Glucose transporters and insulin action. Implications for insulin resistance and diabetes mellitus. *N Engl J Med* 341:248–257
- Pessin JE, Saltiel AR (2000) Signaling pathways in insulin action: molecular targets of insulin resistance. *J Clin Invest* 106:165–169
- McCowen KC, Malhotra A, Bistrain BR (2001) Stress-induced hyperglycemia. *Crit Care Clin* 17:107–124
- Frankenfield DC, Omert LA, Badellino MM, Wiles CE, III, Bagley SM, Goodarzi S, Siegel JH (1994) Correlation between measured energy expenditure and clinically obtained variables in trauma and sepsis patients. *J Parenter Enteral Nutr* 18:398–403
- Agwunobi AO, Reid C, Maycock P, Little RA, Carlson GL (2000) Insulin resistance and substrate utilization in human endotoxemia. *J Clin Endocrinol Metab* 85:3770–3778
- Gelb AW, Bayona NA, Wilson JX, Cechetto DF (2002) Propofol anesthesia compared to awake reduces infarct size in rats. *Anesthesiol* 96:1183–1190
- Sakurai Y, Zhang XJ, Wolfe RR (1996) TNF directly stimulates glucose uptake and leucine oxidation and inhibits FFA flux in conscious dogs. *Am J Physiol* 270:E864–E872
- Lang CH, Dobrescu C (1991) Gram-negative infection increases noninsulin-mediated glucose disposal. *Endocrinology* 128:645–653
- Meszaros K, Lang CH, Bagby GJ, Spitzer JJ (1987) Tumor necrosis factor increases in vivo glucose utilization of macrophage-rich tissues. *Biochem Biophys Res Commun* 149:1–6
- Bird TA, Davies A, Baldwin SA, Saklatvala J (1990) Interleukin 1 stimulates hexose transport in fibroblasts by increasing the expression of glucose transporters. *J Biol Chem* 265:13578–13583
- Green CJ, Campbell IT, O'Sullivan E, Underhill S, McLaren DP, Hipkin LJ, MacDonald IA, Russell J (1995) Septic patients in multiple organ failure can oxidize infused glucose, but non-oxidative disposal (storage) is impaired. *Clin Sci* 89:601–609
- Saeed M, Carlson GL, Little RA, Irving MH (1999) Selective impairment of glucose storage in human sepsis. *Br J Surg* 86:813–821
- Mizock BA (1997) Alterations in fuel metabolism in critical illness. Hyperglycemia. In: Ober KP (ed) *Endocrinology of critical disease*. Humana Press, Totawa, New Jersey, pp 197–297

34. Mesotten D, Delhanty PJ, Vanderhoydonc F, Hardman KV, Weekers F, Baxter RC, Van den BG (2002) Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. *J Clin Endocrinol Metab* 87:5516–5523
35. Jeevanandam M, Young DH, Schiller WR (1990) Glucose turnover, oxidation, and indices of recycling in severely traumatized patients. *J Trauma* 30:582–589
36. Cerra FB (1987) Hypermetabolism, organ failure, and metabolic support. *Surgery* 101:1–14
37. Wolfe RR (1997) Substrate utilization/insulin resistance in sepsis/trauma. *Baillieres Clin Endocrinol Metab* 11:645–657
38. Petit F, Bagby GJ, Lang CH (1995) Tumor necrosis factor mediates zymosan-induced increase in glucose flux and insulin resistance. *Am J Physiol* 268:E219–E228
39. Roh MS, Moldawer LL, Ekman LG, Dinarello CA, Bistrian BR, Jeevanandam M, Brennan MF (1986) Stimulatory effect of interleukin-1 upon hepatic metabolism. *Metabolism* 35:419–424
40. Lang CH (1992) Sepsis-induced insulin resistance in rats is mediated by a beta-adrenergic mechanism. *Am J Physiol* 263:E703–E711
41. Chambrier C, Laville M, Rhzioual BK, Odeon M, Bouletreau P, Beylot M (2000) Insulin sensitivity of glucose and fat metabolism in severe sepsis. *Clin Sci* 99:321–328
42. Aljada A, Ghanim H, Assian E, Dandona P (2002) Tumor necrosis factor- α inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. *Metabolism* 51:487–491
43. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF- α - and obesity-induced insulin resistance. *Science* 271:665–668
44. Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A (1995) Tumor necrosis factor α -induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. *J Biol Chem* 270:23780–23784
45. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y (1997) A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. *J Biol Chem* 272:29911–29918
46. Nunes AL, Carnevalheira JB, Carvalho CR, Brenelli SL, Saad MJ (2001) Tissue-specific regulation of early steps in insulin action in septic rats. *Life Sci* 69:2103–2112
47. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM (1994) Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor- α . *J Clin Invest* 94:1543–9
48. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM (1994) Tumor necrosis factor α inhibits signaling from the insulin receptor. *Proc Natl Acad Sci USA* 91:4854–4858
49. Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ, Ye J (2002) Serine phosphorylation of insulin receptor substrate 1 by inhibitor κ B kinase complex. *J Biol Chem* 277:48115–48121
50. Gay NJ, Keith FJ (1991) Drosophila Toll and IL-1 receptor. *Nature* 351:355–356
51. Belvin MP, Anderson KV (1996) A conserved signaling pathway: the Drosophila toll-dorsal pathway. *Annu Rev Cell Develop Biol* 12:393–416
52. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S (1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. *J Immunol* 162:3749–3752
53. Barnes PJ, Karin M (1997) Nuclear factor- κ B-A pivotal transcription factor in chronic inflammatory diseases. *N Engl J Med* 336:1066–1071
54. Chiasson JL, Shikama H, Chu DT, Exton JH (1981) Inhibitory effect of epinephrine on insulin-stimulated glucose uptake by rat skeletal muscle. *J Clin Invest* 68:706–713
55. Haring H, Kirsch D, Obermaier B, Ermel B, Machicao F (1986) Decreased tyrosine kinase activity of insulin receptor isolated from rat adipocytes rendered insulin-resistant by catecholamine treatment in vitro. *Biochem J* 234:59–66
56. Dimitriadis G, Leighton B, Parry-Billings M, Sasson S, Young M, Krause U, Bevan S, Piva T, Wegener G, Newsholme EA (1997) Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. *Biochem J* 321:707–712
57. Smith TR, Elmendorf JS, David TS, Turinsky J (1997) Growth hormone-induced insulin resistance: role of the insulin receptor, IRS-1, GLUT-1, and GLUT-4. *Am J Physiol* 272:E1071–E1079
58. Dominici FP, Cifone D, Bartke A, Turyn D (1999) Alterations in the early steps of the insulin-signaling system in skeletal muscle of GH-transgenic mice. *Am J Physiol* 277:E447–E454
59. Khaodhiar L, McCowen K, Bistrian B (1999) Perioperative hyperglycemia, infection or risk? *Curr Opin Clin Nutr Metab Care* 2:79–82
60. Norhammar AM, Ryden L, Malmberg K (1999) Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. *Diabetes Care* 22:1827–1831
61. Zindrou D, Taylor KM, Bagger JP (2001) Admission plasma glucose: an independent risk factor in nondiabetic women after coronary artery bypass grafting. *Diabetes Care* 24:1634–1639
62. Malmberg K, Norhammar A, Wedel H, Ryden L (1999) Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. *Circulation* 99:2626–26232
63. Malmberg K (1997) Prospective randomized study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. *Br Med J* 314:1512–1515
64. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L (1995) Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. *J Am Coll Cardiol* 26:57–65

65. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC (2001) Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. *Stroke* 32:2426–2432
66. Woo J, Lam CW, Kay R, Wong AH, Teoh R, Nicholls MG (1990) The influence of hyperglycemia and diabetes mellitus on immediate and 3-month morbidity and mortality after acute stroke. *Arch Neurol* 47:1174–1177
67. Dandona P, Aljada A, Bandyopadhyay A (2003) The potential therapeutic role of insulin in acute myocardial infarction in patients admitted to intensive care and in those with unspecified hyperglycemia. *Diabetes Care* 26:516–519
68. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, van den Berghe G (2003) Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. *J Clin Endocrinol Metab* 88:1082–1088
69. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P (2000) Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. *J Clin Endocrinol Metab* 85:2970–2973
70. Straczkowski M, Dzienis-Straczkowska S, Stepien A, Kowalska I, Szelachowska M, Kinalska I (2002) Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor- α system. *J Clin Endocrinol Metab* 87:4602–4606
71. Chettab K, Zibara K, Belaiba SR, McGregor JL (2002) Acute hyperglycemia induces changes in the transcription levels of 4 major genes in human endothelial cells: macroarray-based expression analysis. *Thromb Haemost* 87:141–148
72. Standiford TJ, Kunkel SL, Greenberger MJ, Laichalk LL, Strieter RM (1996) Expression and regulation of chemokines in bacterial pneumonia. *J Leukoc Biol* 59:24–28
73. Hack CE, Aarden LA, Thijs LG (1997) Role of cytokines in sepsis. *Adv Immunol* 66:101–195
74. Multz AS, Cohen R (2003) Systemic response to pneumonia in the critically ill patient. *Semin Resp Infect* 18:68–71
75. Aljada A, Ghanim H, Mohanty P, Hofmeyer D, Tripathy D, Dandona P (2002) Glucose activates nuclear factor kappa B pathway in mononuclear cells (MNC) and induces an increase in p47phox. subunit in MNC membranes [Abstract]. *Diabetes* 51 (Suppl 2):A537
76. Yorek MA, Dunlap JA (2002) Effect of increased concentration of D-glucose or L-fucose on monocyte adhesion to endothelial cell monolayers and activation of nuclear factor-kappaB. *Metabolism* 51:225–234
77. Guha M, Bai W, Nadler JL, Natarajan R (2000) Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. *J Biol Chem* 275:17728–17739
78. Ceriello A, Bortolotti N, Motz E, Pieri C, Marra M, Tonutti L, Lizzio S, Feletto F, Catone B, Taboga C (1999) Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. *Metabolism* 48:1503–1508
79. Ceriello A (1993) Coagulation activation in diabetes mellitus: the role of hyperglycemia and therapeutic prospects. *Diabetologia* 36:1119–1125
80. Aljada A, Ghanim H, Mohanty P, Syed T, Dandona P (2003) Glucose intake induces an increase in AP-1 and Egr-1 in mononuclear cells and plasma matrix metalloproteinases and tissue factor (TF) concentrations. *J Clin Endocrinol Metab*
81. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F (1997) Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. *Circulation* 95:1783–1790
82. Pozzilli P, Leslie RD (1994) Infections and diabetes: mechanisms and prospects for prevention. *Diabet Med* 11:935–941
83. Mowlavi A, Andrews K, Milner S, Herndon DN, Heggors JP (2000) The effects of hyperglycemia on skin graft survival in the burn patient. *Ann Plast Surg* 45:629–632
84. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A (1999) Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. *Ann Thorac Surg* 67:352–360
85. Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, Kanhere V, Starr A (1997) Glucose control lowers the risk of wound infection in diabetics after open heart operations. *Ann Thorac Surg* 63:356–361
86. McManus LM, Bloodworth RC, Prihoda TJ, Blodgett JL, Pinckard RN (2001) Agonist-dependent failure of neutrophil function in diabetes correlates with extent of hyperglycemia. *J Leukoc Biol* 70:395–404
87. Evans TW (2001) Hemodynamic and metabolic therapy in critically ill patients. *N Engl J Med* 345:1417–1418
88. Rassias AJ, Marrin CA, Arruda J, Whalen PK, Beach M, Yeager MP (1999) Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. *Anesth Analg* 88:1011–1016
89. Nielson CP, Hindson DA (1989) Inhibition of polymorphonuclear leukocyte respiratory burst by elevated glucose concentrations in vitro. *Diabetes* 38:1031–1035
90. Kwoun MO, Ling PR, Lydon E, Imrich A, Qu Z, Palombo J, Bistrrian BR (1997) Immunologic effects of acute hyperglycemia in nondiabetic rats. *J Parenter Enteral Nutr* 21:91–95
91. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S (2001) Insulin inhibits intranuclear nuclear factor kappaB and stimulates I κ B in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? *J Clin Endocrinol Metab* 86:3257–3265
92. Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P (2002) Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. *J Clin Endocrinol Metab* 87:1419–1422
93. Aljada A, Dandona P (2000) Effect of insulin on human aortic endothelial nitric oxide synthase. *Metabolism* 49:147–150
94. Peng HB, Spiecker M, Liao JK (1998) Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. *J Immunol* 161:1970–1976
95. Spiecker M, Darius H, Kaboth K, Hubner F, Liao JK (1998) Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. *J Leukoc Biol* 63:732–739

96. Spiecker M, Peng HB, Liao JK (1997) Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IkappaBalpha. *J Biol Chem* 272:30969–30974
97. Meldrum DR, McIntyre RC, Sheridan BC, Cleveland JC Jr, Fullerton DA, Harken AH (1997) L-arginine decreases alveolar macrophage proinflammatory monokine production during acute lung injury by a nitric oxide synthase-dependent mechanism. *J Trauma* 43:888–893
98. Laroux FS, Lefer DJ, Kawachi S, Scalia R, Cockrell AS, Gray L, van der Heyde H, Hoffman JM, Grisham MB (2000) Role of nitric oxide in the regulation of acute and chronic inflammation. *Antioxidants Redox Signaling* 2:391–396
99. Torre A de la, Schroeder RA, Punzalan C, Kuo PC (1999) Endotoxin-mediated S-nitrosylation of p50 alters NF-kappa B-dependent gene transcription in ANA-1 murine macrophages. *J Immunol* 162:4101–4108
100. Walley KR, McDonald TE, Higashimoto Y, Hayashi S (1999) Modulation of proinflammatory cytokines by nitric oxide in murine acute lung injury. *Am J Respir Crit Care Med* 160:698–704
101. Pahl HL (1999) Activators and target genes of rel/NF-kappaB transcription factors. *Oncogene* 18:6853–6866
102. Bohrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Mannel D, Bottiger BW, Stern DM, Waldherr R, Saeger HD, Ziegler R, Bierhaus A, Martin E, Nawroth PP (1997) Role of NFkappaB in the mortality of sepsis. *J Clin Invest* 100:972–985
103. Arnalich F, Garcia-Palomero E, Lopez J, Jimenez M, Madero R, Renart J, Vazquez JJ, Montiel C (2000) Predictive value of nuclear factor kappaB activity and plasma cytokine levels in patients with sepsis. *Infect Immunol* 68:1942–1945
104. Paterson RL, Galley HF, Dhillon JK, Webster NR (2000) Increased nuclear factor kappa B activation in critically ill patients who die. *Crit Care Med* 28:1047–1051
105. Marik PE (2002) Nuclear factor-kappaB inhibition in sepsis: steroids versus specific nuclear factor-kappaB inhibitors? *Crit Care Med* 30:2393–2394
106. Christman JW, Lancaster LH, Blackwell TS (1998) Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. *Intensive Care Med* 24:1131–1138
107. Fink MP (2003) Nuclear factor-kB: Is it a therapeutic target for the adjuvant treatment of sepsis. *Crit Care Med* 31:2400–2402
108. Liu SF, Ye X, Malik AB (1999) Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. *Circulation* 100:1330–1337
109. Marik PE, Zaloga G (2003) Gastric vs post-pyloric feeding? A systematic review. *Intensive Care Med*
110. Marik PE, Zaloga GP (2001) Early enteral nutrition in acutely ill patients: a systematic review. *Crit Care Med* 29:2264–2270
111. Marik PE, Pinsky MR (2003) Death by total parenteral nutrition. *Intensive Care Med* 29:867–869
112. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, Hamouda W, Dandona P (2001) Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. *J Clin Endocrinol Metab* 86:1306–1312
113. Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P (2001) Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? *J Clin Endocrinol Metab* 86:3250–3256
114. Yue TI TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH (2001) In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. *Circulation* 104:2588–2594
115. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C (2002) Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. *FASEB J* 16:1027–1040